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Background: To assess pathological correlations and temporal trends of Angiopoietin-2 (ANGPT2), vascular
endothelial growth factor (VEGF) and M2 Pyruvate kinase (TuM2PK), markers of tumor vascular development and
metabolism, in patients with renal cell carcinoma (RCC).
Methods: We prospectively collected plasma samples from 89 patients who underwent surgical/ablative therapy
for RCC and 38 patients with benign disease (nephrolithiasis, hematuria without apparent neoplastic origin, or
renal cysts). In RCC patients, marker levels were compared between at least 1 preoperative and 1 postoperative
time point generally 3 weeks after surgery. Marker temporal trends were assessed using the Wilcoxon sign-rank
test. Plasma VEGF, ANGPT2, and TuM2PK levels were determined by ELISA and tested for association with
pathological variables.
Results: Median age was comparable between groups. 83/89 (93%) of the cohort underwent surgical
extirpation. 82% of the tumors were organ confined (T ≤2, N0). Only ANGPT2 exhibited significantly elevated
preoperative levels in patients with RCC compared to benign disease (p = 0.046). Elevated preoperative levels of
ANGPT2 and TuM2PK significantly correlated with increased tumor size and advanced grade (p < 0.05).
Chromophobe RCC exhibited higher levels of ANGPT2 compared to other histologies (p < 0.05). A decline in
marker level after surgery was not observed, likely due to the timing of the analyses.
Conclusion: Our results suggest that ANGPT2 is a marker of RCC. Additionally, ANGPT2 and TuM2PK significantly
correlated with several adverse pathological features. Further studies are needed to determine clinical applicability.
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In 2014, 63920 new diagnoses, and 13860 deaths attrib-
uted to tumors of the kidney and renal pelvis are
expected [1]. 5-year cancer specific survival (CSS) prob-
ability rates for patients with localized and locally
advanced disease are around 80-90% and 20-50%, re-
spectively [2]. Advances in surgical techniques and the
development of targeted therapies have lead to* Correspondence: Vitaly.Margulis@utsouthwestern.edu
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unless otherwise stated.improved oncologic outcomes of patients with RCC,
however, survival of patients with advanced disease
continues to be deficient [3]. A better understanding
of the biology of tumors is required to improve onco-
logical outcomes.
Central to the development of RCC of clear-cell type
(ccRCC) is the loss of VHL with activation of a hypoxia-
adaptive program that involves metabolic changes and
angiogenesis. Our understanding of the nature of ccRCC
has led to the development of targeted agents that
antagonize VEGF signaling [4]. Currently, therapies tar-
get the VEGF ligand or its receptor. Other determinants
of angiogenesis are being investigated, including Angio-
poietin 2 (ANGPT2) [5,6]. ANGPT2 is found at sites ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cular foundation [7].
Loss of VHL induces profound metabolic changes. For
instance, we recently showed that VHL inactivation in
the mouse is sufficient to inhibit mitochondrial respir-
ation [8]. Tumor cells often rely on aerobic glycolysis for
energy generation, which makes carbon sources available
for anabolic processes. One protein that plays a critical
role in tumor metabolism is pyruvate kinase. Several
isoforms of this enzyme exist, however, the M2 isoform
(M2PK) is specifically implicated in oncogenesis, and is
overexpressed in tumor cells [9]. Studies have shown
that the dimeric form (TuM2PK) may be a marker of
malignant renal disease [10]. In addition, TuM2PK may
be a useful predictor of recurrence in patients with RCC
[11]. However, the current role of TuM2PK continues to
be undefined.
Currently, prognostic factors such as stage and grade
fail to incorporate the individual biological heterogeneity
and clinical behavior of RCC [12]. Thus, there is a strong
impetus for detecting and incorporating biomarkers into
clinical practice that expose the biological behavior of
tumors and aid in risk assessment [13].
In this prospective feasibility study, we analyzed a
panel of potential RCC markers (VEGF, TuM2PK, and
ANGPT2) in patients with RCC vs. a control group with
benign renal disease. We correlated the levels of the
marker with pathologic features of the tumor at surgery
and evaluated the levels postoperatively.
Methods
Patient selection
Between October 2008 and March 2010, patients pre-
senting to the UT Southwestern Medical Center Urology
Clinic with a renal mass suspicious for RCC as well
those with presumed benign etiology were enrolled in an
UT Southwestern Medical Center IRB approved tissue
and blood repository protocol. Patients enrolled in the
study signed written consent. Research was carried out
in compliance with the Helsinki Declaration. 125 pa-
tients were followed from the time of diagnosis to at
least 2 preoperative time points and 1 postoperative time
point taken more than 24 h after surgery. Of these, 9
presented with metastatic disease and 3 patients devel-
oped other malignancies, and were withdrawn, leaving
113 patients (102 underwent surgical nephrectomy and
11 radiofrequency ablation). Benign pathology was re-
ported in 13 surgical patients and 5 additional patients
were withdrawn because were not left NED after sur-
gery. 5 patients treated with ablative intervention had ei-
ther no biopsy, were benign, or insufficient material was
available. After applying these criteria, 90 patients
qualified for this analysis and 89 underwent ELISA as-
says. 38 patients qualified as controls with either ofthe following benign conditions: nephrolithiasis,
hematuria of presumed benign etiology, or simple
renal cysts. Computerized tomography (CT) scans were
used to evaluate urologic conditions and establish radio-
logic absence of malignancy. Further, patients with
hematuria also underwent complete workup, including
cytology, imaging, and cystoscopy to rule out malignancy.
Collection and storage of samples
Peripheral venous blood was collected from patients
with RCC at preoperative and postoperative time points.
Patients serving as controls had blood drawn at their ini-
tial clinic visit. Blood was collected in EDTA tubes, and
centrifuged, typically within 15 minutes. Plasma samples
were aliquoted and stored at −80°C until analysis.
Elisa assays
Plasma from each pre and postoperative time point was
evaluated. Serum samples, collected for other purposes,
were not used for this study as platelet degranulation
during clotting may lead to falsely elevated levels of the
marker [14]. Plasma VEGF and ANGPT2 levels were
determined by ELISA according to the manufacturer’s
instructions (R & D Systems, Minneapolis, MN, USA).
Plasma TuM2PK levels were also determined by ELISA
according to the manufacturer’s instructions (ScheBo,
Wettenberg, Germany). Each time point was run in
duplicate and all samples for each patient were run on
the same plate. Standards and a set of controls were run
on each plate. ELISA results for each marker were dis-
played as heatmaps by normalizing the values of each
patient to the number of standard deviations above or
below the average.
Statistics
Patient characteristics are displayed using medians,
ranges, frequencies, and percentages. Where applicable,
marker levels were calculated as the patient’s average
preoperative draw and the average postoperative draw.
To evaluate marker trends over time the Wilcoxon sign-
ranks test was used. Wilcoxon rank sum test was used
to find if there was a difference between RCC patients
and control patients. All statistics were performed using
software from GraphPad Prism version 5.03 (GraphPad
Software, San Diego, CA, USA) and SAS version 9.3
(SAS Institute Inc., Cary, NC, USA). A p-value < 0.05
was considered significant. False discovery rate control
was used for the p-values from the testing between
marker levels and pathological variables.
Results
Clinical features
Table 1 outlines the demographic and clinical character-
istics of both cohorts. A total of 127 patients were
Table 1 Characteristics of RCC and control patients
Variable RCC (n = 89) Controls (n = 38)
Age Median (range) 62 (25-85) 57 (23-89)
Sex - no. (%)
Male 52 (58.4) 20 (52.6)
Female 37 (41.6) 18 (47.4)
Race - no. (%)
Caucasian 66 (74.2) 28 (70.0)
African American 9 (10.1) 6 (15.0)
Hispanic 9 (10.1) 6 (15.0)
East Indian 4 (4.5) 0
Asian 1 (1.1) 0




Renal Cyst 2 (5.3)





















Pathologic Size† - median (range) 4.1 (1.3-25)




Histology - no. (%)
Clear Cell 69 (77.5)
Papillary 14 (15.7)
Table 1 Characteristics of RCC and control patients
(Continued)
Chromophobe 5 (5.6)
Unclassified RCC 1 (1.1)





†Analysis does not include patients treated with RFA.
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of their renal mass and 38 patients presented with
benign conditions that served as the control group. The
two groups were comparable with respect to age, gender,
and race. 83/89 (93%) patients with renal masses under-
went extirpative resection, with either partial or radical
nephrectomy. 82% of the tumors were organ confined
(pT ≤2, N0) and 78% had clear cell histology.
Association of marker levels with malignancy
Median time between the operation and the last postop-
erative draw was 25 days (interquartile range 18–187
days). ANGPT2 exhibited significantly elevated pre-
operative levels in patients with RCC (p = 0.046) com-
pared to those with benign disease, while preoperative
TuM2PK and VEGF levels were comparable between
patients with benign and malignant disease (Figure 1).
Temporal changes of markers
Figure 2 is a heatmap representation of the different
markers for each patient over time.
Table 2 shows how marker levels are affected over
time. We calculated the median difference of 1st postop-
erative levels vs. the average of all the preoperative levels
(which we perceived to be most representative of pre-
operative levels). Our results showed that ANGPT2 and
TuM2PK levels increased significantly. Similar results
were observed when all postoperative samples were
included in the analysis.
When the first postoperative sample was excluded
(despite being ~3 weeks after the surgery), the differ-
ences largely disappeared. In keeping with this find-
ing, there was a significant difference in ANGPT2
and TuM2PK levels between the first and remaining
postop values. Overall, these data are consistent with
the notion that surgery induces plasma ANGPT2 and
TuM2PK levels.
Association of pathological features with markers levels
Interestingly, elevated preoperative levels of ANGPT2
and TuM2PK significantly correlated with several ad-
verse pathological features (Figure 3). There was a
Figure 1 Wilcoxon rank sum test for differences in marker levels for 1st preoperative time point versus controls.
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tumor size (p = 0.0009). Similarly, TuM2PK levels were
also correlated with tumor size (p = 0.0009). In addition,
there was a correlation between ANGPT2 and TuM2PK
and grade. Higher levels of both ANGPT2 and TuM2PK
were observed in grade 4 tumors (p < 0.05). In addition,
chromophobe RCC exhibited significantly higher levels
of ANGPT2 compared to other histologies (p < 0.05)
(Figure 3). No correlation was seen between VEGF levels
and adverse pathological features.Discussion
Circulating tumor biomarkers may assist with primary
diagnosis, determination of recurrence and prognosis.
However, no suitable renal cancer biomarkers have been
identified and incorporated in clinical practice. In this
study, we explored a sensitive paradigm. We evaluated
samples from patients with a primary in place and
performed comparisons of circulating proteins before
and after surgery. Intra-patient comparisons are likely to
minimize confounding by other variables. In addition,
we compared biomarker levels between renal cancer
patients and a group of controls with non-malignant
disease. By enrolling surgical candidates, we were able to
correlate circulating biomarker levels to the pathological
features of the tumor. We focused our studies on VEGF,
ANGPT2 and TuM2PK.
One pathway that is being extensively studied is the
angiopoietin/Tie-2 pathway. This pathway is comprised
not only of angiopoietin 1 (ANGPT1), but also of
ANGPT2, and its receptor vascular receptor tyrosine
kinase Tie-2. These factors play a significant role in neo-
vascularization [15,16]. ANGPT1 has been shown to be
involved in vascular development, while ANGPT2 func-
tions to undermine vascular integrity [7,15]. ANGPT2
overexpression has also been shown to augment tumor
angiogenesis [17]. Sallinen et al. showed that patients
with ovarian carcinoma had significantly higher levels of
ANGPT2 than individuals with benign disease. Further,elevated ANGPT2 levels correlated with advanced stage
as well as worse DFS and OS [18]. Others have shown
that ANGPT2 to be a biomarker of disease status,
adverse pathological features, and worse oncological
outcomes [19,20]. While the definitive role of ANGPT2
in RCC remains undefined, studies exist showing that
ANGPT2 concentrations appear to be elevated in
patients with RCC [21,22]. Efforts are also ongoing to
target angiopoietin/Tie-2 system with drugs such as
AMG-386 and CVX-060 in patients with RCC [23].
TuM2PK has been implicated as a driver of aerobic
glycolysis, and shown to be a marker of malignancy
in several neoplasms [9]. Landt et al. revealed that
TuM2PK levels can distinguish between malignant
and premalignant cervical lesions. Additionally, they
showed that increased levels of TuM2PK were associ-
ated with node positive as well as metastatic disease
[24]. A recent meta-analysis showed that elevated
TuM2PK levels correlated with malignancy as well as
extent of disease in patients with GI malignancy [25].
Few reports exist regarding the role of TuM2PK in
patients with RCC. Nisman et al. showed that elevated
levels of TuM2Pk were significantly associated with
worse pathological features, including grade and tumor
necrosis [11]. Their results also revealed that patients
with elevated circulating TuM2PK had worse 5-year RFS
than patients with normal marker levels (55% vs. 94%
p < 0.001). On multivariate analysis, TuM2PK was an
independent predictor of disease recurrence (p = 0.04)
[11]. In an interesting study by Roigas et al. plasma
levels of TuM2PK were compared between healthy
patients and patients with RCC. Elevated levels of
TuM2PK were significantly elevated in patients with
RCC than healthy patients [26]. Conversely, Varga
et al. concluded that TuM2PK is not an adequate
marker for RCC [27].
In our study, we prospectively analyzed the prognostic
significance of 3 markers of angiogenesis and metabol-
ism. Most importantly, elevated preoperative levels of
ANGTP2 and TuM2PK were significantly associated
Figure 2 Heatmap representation of VEGF, M2PK, and ANGPT2 plasma levels by patient, over time. For each marker and patient, values were
normalized to the number of standard deviations above (red) of below (blue) the average. Samples are arranged in chronological order for each patient.
The number of samples available for each patient varies, and isolated gray boxes for a particular patient represent missing values for the particular analysis.
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Table 2 Wilcoxon signed rank test for median of difference in marker levels between pairs of time points
1st post – Avg.
Preoperative
Avg. all but 1st post –
Avg. preoperative
Avg. all post – Avg.
preoperative
Avg. all but 1st Post – 1st
postoperative
n Median p n Median p n Median p n Median p
ANGPT2 88 318.1 0.0004 26 2.4 0.3914 88 253.1 0.0082 26 −300.2 <0.0001
M2PK 89 13.0 <0.0001 27 −2.1 0.2880 89 12.4 <0.0001 27 −8.6 0.0003
VEGF 89 −6.1 0.2021 23 −2.2 0.1973 89 −4.0 0.3581 23 4.0 0.6799
Figure 3 Pathological features and association with marker levels.
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and grade.
While anti-VEGF therapies have become mainstay of
treatment for patients with metastatic clear cell RCC,
the role and efficacy of targeted therapies in non-clear
cell variants remains unclear [28]. Developing therapies
based on molecular markers specific for other histologies
could improve oncological outcomes. In our study,
ANGTP2 levels were significantly higher in patients with
chromophobe RCC, than those with either clear cell or
papillary RCC, suggesting that ANGPT2/TIE2 system
may play a particularly important role in chromophobe
tumors and may serve as a target for therapy. However,
not all chromophobe samples exhibited the same degree
of ANGPT2 elevation.
Disappointingly, temporal trends did not show the
predicted decrease in marker levels that we expected.
This could be due to several reasons. The short follow-
up of the study did not allow for enough time for the
marker levels to decrease. Also, the timing of when
marker samples were collected could account for the
variability in levels. However, currently the timing of
when marker samples should be collected remains
undefined. Nevertheless, some reports show that it may
take 11 weeks for elevated levels of TuM2PK to
normalize [10].
The definitive goal of developing novel biomarkers
would be incorporation into current prognostic tools.
Novel markers, such as ANGPT2 and TuM2PK could
improve oncological outcomes in patients with RCC
by identifying patients who may benefit from a par-
ticular therapy, thus individualizing treatment plans.
Biomarker-based scoring algorithms, such as the Bio-
Score, which is based on the expression levels of B7-
H1, survivin, and Ki67, help to predict the likelihood
of RCC specific death [29]. Individuals with high Bio-
scores are associated with a higher rate of death from
RCC than individuals with low BioScores [29]. Thus,
biomarker incorporation into current prognostic models
could serve as an excellent risk stratification tool that both
individualizes therapy and as well as directs treatment.
Our study has several limitations. The number of
patients is modest. While we concluded that elevated
marker levels were significantly seen in certain subtypes
of RCC, our data is still limited by the number of
patients included in the study. As with prospective stud-
ies, results are based on availability of samples postoper-
atively and patient follow up. Despite these challenges,
our study does show significant associations between
some markers and adverse pathological parameters.
Conclusion
In our preliminary study, plasma levels of ANGPT2 and
TuM2PK obtained prior to ablation or surgery for renalmasses, were increased compared to controls and were
associated with several aggressive pathological features
including tumor size and grade. Our findings support
further research into the role of circulating proteins as a
means to augment current prognostic predictors of out-
come in patients with kidney cancer.
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